Max Healthcare Institute Limited (MAXHEALTH), one of India’s largest private sector healthcare service providers, announced its financial and operating results for the second quarter and half year ended September 30, 2026. The company’s network gross revenue rose to ₹3,219 crore, marking a 20% year-on-year growth. The profit after tax (PAT) stood at ₹448 crore, up 10% compared to the same period last year.

Key Financial Highlights

The company’s PAT for Q2 FY27 was ₹448 crore, compared to ₹406 crore in Q2 FY26 and ₹357 crore in Q1 FY27, reflecting a growth of 10% year-on-year. The operational bed capacity at the end of September 2026 was 5,518, up by 758 beds (+16% YoY) compared to September 2025. The bed occupancy for the quarter was at 77%, with occupied bed days (OBDs) up by 13% year-on-year.

Operational Performance

During the quarter, over 31 lakh episodes of patient services were delivered across the network, reflecting a growth of 12% year-on-year. The average revenue per inpatient patient (ARPP) for Q2 FY27 stood at ₹2.31 lakh, compared to ₹2.14 lakh in Q2 FY26 and ₹2.30 lakh in Q1 FY27, representing a growth of 8% year-on-year. Free cash from operations was ₹500 crore in Q2 FY27 compared with ₹291 crore in Q2 FY26 and ₹397 crore in Q1 FY27. Of this, ₹292 crore was invested in ongoing expansion plans and ₹195 crore was disbursed towards dividends.

Future Outlook

The board has approved capital expenditure of ₹415 crore for the addition of 209 brownfield beds across existing hospitals. This includes 85 beds at MSSH, Noida, 60 beds at MSSH, Vaishali, and 64 beds at BLK Max Delhi. The company continues to focus on expanding its capacity to meet the growing demand for quality healthcare in India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max Healthcare Institute Limited

Max Healthcare Institute Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max drops 22.4% over three months and trades near its 52-week lows. The PEG stands at 6.10 — severely stretched. Any earnings miss could trigger a sharp de-rating. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. RSI stands at 24, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. The business compounds at 22.4% revenue and 9.3% profit CAGR, with D/E of 0.00. Yet the stock drops 22.4% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Max Healthcare Institute Limited.

OneSource Specialty Pharma Limited (NSE: ONESOURCE) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a ‘Voluntary Action Indicated’ (VAI) classification. This follows an inspection conducted from June 22 to June 30, 2026. This development highlights the company’s commitment to maintaining high standards of quality, regulatory compliance, and operational excellence.

Regulatory Milestone

The EIR with VAI classification signifies a regulatory milestone for OneSource. Neeraj Sharma, Managing Director & CEO, commented, “We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This outcome reflects our continued dedication to quality and compliance across our operations.”

Strategic Importance

The SPD facility plays a crucial role in OneSource’s sterile manufacturing capabilities, enabling the company to support the evolving needs of its global partners. This achievement adds to OneSource’s robust regulatory track record as it continues to build a globally competitive CDMO platform.

Future Outlook

As OneSource advances its capabilities in drug-device combinations, biologics, sterile injectables, and soft gelatin capsules, this milestone positions the company for continued growth and success in the pharmaceutical manufacturing sector. The company remains focused on delivering efficient, end-to-end solutions to its global clientele.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Onesource falls 14.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 232.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 14.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Onesource Specialty Pharma Limited.

Wanbury Limited (NSE: WANBURY) is pleased to announce that its manufacturing facility at Tanuku, Andhra Pradesh, has successfully received the Good Manufacturing Practice (GMP) Compliance Certificate from Australia’s Therapeutic Goods Administration (TGA), the regulatory authority responsible for therapeutic goods in Australia. This certification marks an important milestone in Wanbury’s commitment to manufacturing excellence, stringent quality standards, and strengthening its presence in regulated international pharmaceutical markets.

Successful Inspection and Compliance

Following a successful inspection conducted by the TGA on 8–9 June 2026, the Australian regulatory authority confirmed that the manufacturing facility complies with the applicable Good Manufacturing Practice requirements outlined in the PIC/S Guide to Good Manufacturing Practice for Medicinal Products. The certificate covers the manufacturing of six Active Pharmaceutical Ingredients (APIs): Metformin Hydrochloride, Tramadol Hydrochloride, Sertraline Hydrochloride, Diphenhydramine Hydrochloride, Mefenamic Acid, and Paroxetine Hydrochloride Hemihydrate.

A Step Forward in Global Growth

This achievement reinforces Wanbury’s focus on building globally compliant manufacturing capabilities and expanding its footprint across international markets. Recognition by a stringent regulatory authority such as Australia’s TGA further strengthens the company’s quality credentials and its ability to serve customers and partners in regulated pharmaceutical markets. The certification represents another significant milestone in Wanbury’s journey towards operational excellence, regulatory compliance, and sustainable business growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 42.1% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock sits at 16% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.